The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo ...

For people with obstructive sleep apnea, Zepbound should be used with a reduced-calorie diet and increased physical activity, drugmaker Eli Lilly said. The US Food and Drug Administration on ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...